A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analysesCAMERON, David; CASEY, Michelle; CHAN, Arlene et al.Breast cancer research and treatment. 2008, Vol 112, Num 3, pp 533-543, issn 0167-6806, 11 p.Article

Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast CancerLOESCH, David; GRECO, F. Anthony; PIPPEN, John et al.Journal of clinical oncology. 2010, Vol 28, Num 18, pp 2958-2965, issn 0732-183X, 8 p.Article

Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age ≤65 and performance status 2WEISSMAN, Charles H; SANDBACH, John; BROOKER, Reginald et al.Lung cancer. 2006, Vol 52, Num 3, pp 313-317, issn 0169-5002, 5 p.Article

Lapatinib plus capecitabine for HER2-positive advanced breast cancerGEYER, Charles E; FORSTER, John; SKARLOS, Dimosthenis et al.The New England journal of medicine. 2006, Vol 355, Num 26, pp 2733-2743, issn 0028-4793, 11 p.Article

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathyVAHDAT, Linda T; GARCIA, Agustin A; VOGEL, Charles et al.Breast cancer research and treatment. 2013, Vol 140, Num 2, pp 341-351, issn 0167-6806, 11 p.Article

Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancerNEUBAUER, Marcus A; GARFIELD, David H; KUERFLER, Paul R et al.Lung cancer. 2005, Vol 47, Num 1, pp 121-127, issn 0169-5002, 7 p.Article